Share Price and Basic Stock Data
Last Updated: May 31, 2025, 7:43 pm
| PEG Ratio | 1.18 |
|---|
Competitors of Genomic Valley Biotech Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Genomic Valley Biotech Ltd | 13.9 Cr. | 45.6 | 108/33.4 | 38.7 | 12.7 | 0.00 % | 11.8 % | 9.68 % | 10.0 |
| Genesis IBRC India Ltd | 25.0 Cr. | 19.2 | 19.2/13.7 | 7.15 | 6.56 | 0.00 % | 51.6 % | 51.6 % | 10.0 |
| Shreeoswal Seeds & Chemicals Ltd | 130 Cr. | 14.2 | 40.8/11.6 | 4.13 | 0.00 % | 0.62 % | 9.84 % | 2.00 | |
| Nath Bio-Genes (India) Ltd | 357 Cr. | 188 | 264/138 | 8.58 | 341 | 1.06 % | 7.20 % | 6.61 % | 10.0 |
| Continental Seeds and Chemicals Ltd | 26.5 Cr. | 24.1 | 70.2/22.1 | 21.8 | 0.00 % | 10.0 % | 18.0 % | 10.0 | |
| Industry Average | 243.50 Cr | 58.22 | 18.14 | 77.24 | 0.21% | 16.24% | 19.15% | 8.40 |
Quarterly Result
| Metric | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.02 | 0.00 | 1.03 | 0.02 | 0.67 | 1.00 | 0.06 | 0.07 | 0.04 | 0.00 | 0.16 | 0.21 | 0.22 |
| Expenses | 0.05 | 0.32 | 1.08 | 0.05 | 0.63 | 0.07 | 0.03 | 0.05 | 0.02 | 0.04 | 0.03 | 0.07 | 0.06 |
| Operating Profit | -0.03 | -0.32 | -0.05 | -0.03 | 0.04 | 0.93 | 0.03 | 0.02 | 0.02 | -0.04 | 0.13 | 0.14 | 0.16 |
| OPM % | -150.00% | -4.85% | -150.00% | 5.97% | 93.00% | 50.00% | 28.57% | 50.00% | 81.25% | 66.67% | 72.73% | ||
| Other Income | 0.08 | 0.42 | 0.52 | 0.10 | -0.89 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.04 | -0.05 | 0.01 | 0.01 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.01 | 0.15 | 0.46 | 0.06 | -0.85 | 0.98 | 0.03 | 0.02 | 0.02 | -0.04 | 0.13 | 0.15 | 0.16 |
| Tax % | 0.00% | 6.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | 0.01 | 0.15 | 0.46 | 0.06 | -0.85 | 0.98 | 0.03 | 0.02 | 0.02 | -0.04 | 0.13 | 0.15 | 0.16 |
| EPS in Rs | 0.03 | 0.49 | 1.51 | 0.20 | -2.78 | 3.21 | 0.10 | 0.07 | 0.07 | -0.13 | 0.43 | 0.49 | 0.52 |
Last Updated: March 4, 2025, 12:11 pm
Below is a detailed analysis of the quarterly data for Genomic Valley Biotech Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:
- For Sales, as of Dec 2024, the value is 0.22 Cr.. The value appears strong and on an upward trend. It has increased from 0.21 Cr. (Sep 2024) to 0.22 Cr., marking an increase of 0.01 Cr..
- For Expenses, as of Dec 2024, the value is 0.06 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.07 Cr. (Sep 2024) to 0.06 Cr., marking a decrease of 0.01 Cr..
- For Operating Profit, as of Dec 2024, the value is 0.16 Cr.. The value appears strong and on an upward trend. It has increased from 0.14 Cr. (Sep 2024) to 0.16 Cr., marking an increase of 0.02 Cr..
- For OPM %, as of Dec 2024, the value is 72.73%. The value appears strong and on an upward trend. It has increased from 66.67% (Sep 2024) to 72.73%, marking an increase of 6.06%.
- For Other Income, as of Dec 2024, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.01 Cr. (Sep 2024) to 0.00 Cr., marking a decrease of 0.01 Cr..
- For Interest, as of Dec 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Depreciation, as of Dec 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
- For Profit before tax, as of Dec 2024, the value is 0.16 Cr.. The value appears strong and on an upward trend. It has increased from 0.15 Cr. (Sep 2024) to 0.16 Cr., marking an increase of 0.01 Cr..
- For Tax %, as of Dec 2024, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00%.
- For Net Profit, as of Dec 2024, the value is 0.16 Cr.. The value appears strong and on an upward trend. It has increased from 0.15 Cr. (Sep 2024) to 0.16 Cr., marking an increase of 0.01 Cr..
- For EPS in Rs, as of Dec 2024, the value is 0.52. The value appears strong and on an upward trend. It has increased from 0.49 (Sep 2024) to 0.52, marking an increase of 0.03.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: March 7, 2025, 3:54 pm
| Metric | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.03 | 0.09 | 0.03 | 0.11 | 0.44 | 0.59 | 0.99 | 0.85 | 0.21 | 0.07 | 2.72 | 0.17 | 0.59 |
| Expenses | 0.03 | 0.08 | 0.07 | 0.54 | 0.48 | 0.49 | 0.57 | 0.30 | 0.34 | 0.45 | 1.84 | 0.15 | 0.20 |
| Operating Profit | 0.00 | 0.01 | -0.04 | -0.43 | -0.04 | 0.10 | 0.42 | 0.55 | -0.13 | -0.38 | 0.88 | 0.02 | 0.39 |
| OPM % | 0.00% | 11.11% | -133.33% | -390.91% | -9.09% | 16.95% | 42.42% | 64.71% | -61.90% | -542.86% | 32.35% | 11.76% | 66.10% |
| Other Income | 0.01 | 0.01 | 0.07 | 0.16 | 0.01 | 0.03 | 0.01 | 0.01 | 0.00 | 0.50 | -0.22 | 0.00 | 0.01 |
| Interest | 0.00 | 0.01 | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 | 0.18 | 0.18 | 0.04 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.01 | 0.05 | 0.04 | 0.08 | 0.19 | 0.18 | 0.19 | 0.08 | 0.01 | 0.00 | 0.00 |
| Profit before tax | 0.01 | 0.01 | -0.01 | -0.34 | -0.07 | 0.05 | 0.24 | 0.20 | -0.50 | 0.00 | 0.65 | 0.02 | 0.40 |
| Tax % | 0.00% | 0.00% | 0.00% | -2.94% | 0.00% | 40.00% | 0.00% | -40.00% | 12.00% | 0.00% | 0.00% | ||
| Net Profit | 0.00 | 0.00 | -0.01 | -0.33 | -0.07 | 0.03 | 0.23 | 0.29 | -0.56 | -0.01 | 0.65 | 0.02 | 0.40 |
| EPS in Rs | 0.00 | 0.00 | -0.03 | -1.08 | -0.23 | 0.10 | 0.75 | 0.95 | -1.83 | -0.03 | 2.13 | 0.07 | 1.31 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -3200.00% | 78.79% | 142.86% | 666.67% | 26.09% | -293.10% | 98.21% | 6600.00% | -96.92% |
| Change in YoY Net Profit Growth (%) | 0.00% | 3278.79% | 64.07% | 523.81% | -640.58% | -319.19% | 391.32% | 6501.79% | -6696.92% |
Genomic Valley Biotech Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2015-2016 to 2023-2024.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 40% |
| 5 Years: | 0% |
| 3 Years: | 129% |
| TTM: | 394% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 44% |
| 5 Years: | 4% |
| 3 Years: | 42% |
| TTM: | 1700% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 34% |
| 3 Years: | 10% |
| 1 Year: | 23% |
| Return on Equity | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 2% |
| 3 Years: | 12% |
| Last Year: | 10% |
Last Updated: Unknown
Balance Sheet
Last Updated: October 15, 2024, 1:34 pm
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 | 3.05 |
| Reserves | 0.25 | 1.85 | 1.84 | 1.51 | 1.44 | 1.47 | 1.71 | 1.99 | 1.43 | -0.18 | 0.47 | 0.49 | 0.76 |
| Borrowings | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 1.48 | 1.48 | 1.55 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 2.20 | 0.61 | 0.80 | 0.73 | 0.78 | 1.41 | 0.94 | 1.49 | 1.59 | 0.92 | 0.90 | 0.79 | 0.35 |
| Total Liabilities | 6.25 | 6.26 | 6.44 | 6.04 | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.16 |
| Fixed Assets | 3.02 | 3.02 | 3.15 | 3.18 | 3.63 | 4.12 | 4.31 | 4.47 | 5.86 | 1.75 | 0.00 | 0.00 | 0.01 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.38 | 0.49 | 0.49 | 0.49 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.55 | 0.11 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 |
| Other Assets | 3.23 | 3.24 | 2.74 | 2.75 | 2.39 | 2.18 | 2.38 | 3.05 | 1.27 | 2.04 | 4.42 | 4.31 | 4.13 |
| Total Assets | 6.25 | 6.26 | 6.44 | 6.04 | 6.02 | 6.68 | 7.18 | 8.01 | 7.62 | 3.79 | 4.42 | 4.33 | 4.16 |
Below is a detailed analysis of the balance sheet data for Genomic Valley Biotech Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2024, the value is 3.05 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 3.05 Cr..
- For Reserves, as of Sep 2024, the value is 0.76 Cr.. The value appears strong and on an upward trend. It has increased from 0.49 Cr. (Mar 2024) to 0.76 Cr., marking an increase of 0.27 Cr..
- For Borrowings, as of Sep 2024, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2024, the value is 0.35 Cr.. The value appears to be improving (decreasing). It has decreased from 0.79 Cr. (Mar 2024) to 0.35 Cr., marking a decrease of 0.44 Cr..
- For Total Liabilities, as of Sep 2024, the value is 4.16 Cr.. The value appears to be improving (decreasing). It has decreased from 4.33 Cr. (Mar 2024) to 4.16 Cr., marking a decrease of 0.17 Cr..
- For Fixed Assets, as of Sep 2024, the value is 0.01 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 0.01 Cr., marking an increase of 0.01 Cr..
- For CWIP, as of Sep 2024, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Sep 2024, the value is 0.02 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.02 Cr..
- For Other Assets, as of Sep 2024, the value is 4.13 Cr.. The value appears to be declining and may need further review. It has decreased from 4.31 Cr. (Mar 2024) to 4.13 Cr., marking a decrease of 0.18 Cr..
- For Total Assets, as of Sep 2024, the value is 4.16 Cr.. The value appears to be declining and may need further review. It has decreased from 4.33 Cr. (Mar 2024) to 4.16 Cr., marking a decrease of 0.17 Cr..
Notably, the Reserves (0.76 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.75 | -0.74 | -0.79 | -1.18 | -0.79 | -0.65 | -1.06 | -0.93 | -1.68 | -0.38 | 0.88 | 0.02 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
No data available for the Financial Efficiency data table.
No valid data available for the Shareholding
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.05 | 2.12 | -0.03 | -1.83 | 0.94 |
| Diluted EPS (Rs.) | 0.05 | 2.12 | -0.03 | -1.83 | 0.94 |
| Cash EPS (Rs.) | 0.05 | 2.15 | 0.24 | -1.21 | 1.52 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 11.60 | 11.55 | 9.42 | 14.69 | 16.52 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 11.60 | 11.55 | 9.42 | 14.69 | 16.52 |
| Revenue From Operations / Share (Rs.) | 0.54 | 8.91 | 0.23 | 0.68 | 2.77 |
| PBDIT / Share (Rs.) | 0.05 | 3.02 | -0.96 | -0.44 | 1.85 |
| PBIT / Share (Rs.) | 0.04 | 2.99 | -1.24 | -1.06 | 1.26 |
| PBT / Share (Rs.) | 0.04 | 2.12 | -1.38 | -1.64 | 0.67 |
| Net Profit / Share (Rs.) | 0.04 | 2.12 | -0.03 | -1.83 | 0.93 |
| PBDIT Margin (%) | 9.87 | 33.83 | -416.43 | -64.94 | 66.64 |
| PBIT Margin (%) | 9.20 | 33.54 | -535.97 | -155.88 | 45.55 |
| PBT Margin (%) | 9.20 | 23.83 | -596.37 | -241.16 | 24.30 |
| Net Profit Margin (%) | 9.20 | 23.81 | -13.23 | -268.67 | 33.78 |
| Return on Networth / Equity (%) | 0.42 | 18.38 | -0.32 | -12.45 | 5.66 |
| Return on Capital Employeed (%) | 0.42 | 25.89 | -10.55 | -4.80 | 5.32 |
| Return On Assets (%) | 0.35 | 14.66 | -0.24 | -7.33 | 3.57 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.34 | 0.29 |
| Total Debt / Equity (X) | 0.00 | 0.17 | 0.00 | 0.34 | 0.29 |
| Asset Turnover Ratio (%) | 0.03 | 0.66 | 0.01 | 0.02 | 0.11 |
| Current Ratio (X) | 3.68 | 2.88 | 5.31 | 0.18 | 0.52 |
| Quick Ratio (X) | 3.68 | 2.88 | 5.31 | 0.18 | 0.36 |
| Inventory Turnover Ratio (X) | 0.00 | 0.00 | 0.00 | 0.08 | 0.07 |
| Interest Coverage Ratio (X) | 0.00 | 0.00 | -6.89 | -0.76 | 3.14 |
| Interest Coverage Ratio (Post Tax) (X) | 0.00 | 0.00 | -9.05 | -2.15 | 2.59 |
| Enterprise Value (Cr.) | 10.60 | 7.21 | 7.56 | 8.74 | 4.09 |
| EV / Net Operating Revenue (X) | 64.18 | 2.65 | 107.10 | 42.02 | 4.83 |
| EV / EBITDA (X) | 650.07 | 7.83 | -25.72 | -64.70 | 7.24 |
| MarketCap / Net Operating Revenue (X) | 64.22 | 2.44 | 107.14 | 34.64 | 3.12 |
| Price / BV (X) | 2.99 | 1.88 | 2.63 | 1.61 | 0.52 |
| Price / Net Operating Revenue (X) | 64.28 | 2.44 | 107.14 | 34.65 | 3.13 |
| EarningsYield | 0.00 | 0.09 | 0.00 | -0.07 | 0.10 |
After reviewing the key financial ratios for Genomic Valley Biotech Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 24, the value is 0.05. This value is below the healthy minimum of 5. It has decreased from 2.12 (Mar 23) to 0.05, marking a decrease of 2.07.
- For Diluted EPS (Rs.), as of Mar 24, the value is 0.05. This value is below the healthy minimum of 5. It has decreased from 2.12 (Mar 23) to 0.05, marking a decrease of 2.07.
- For Cash EPS (Rs.), as of Mar 24, the value is 0.05. This value is below the healthy minimum of 3. It has decreased from 2.15 (Mar 23) to 0.05, marking a decrease of 2.10.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 11.60. It has increased from 11.55 (Mar 23) to 11.60, marking an increase of 0.05.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 11.60. It has increased from 11.55 (Mar 23) to 11.60, marking an increase of 0.05.
- For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 0.54. It has decreased from 8.91 (Mar 23) to 0.54, marking a decrease of 8.37.
- For PBDIT / Share (Rs.), as of Mar 24, the value is 0.05. This value is below the healthy minimum of 2. It has decreased from 3.02 (Mar 23) to 0.05, marking a decrease of 2.97.
- For PBIT / Share (Rs.), as of Mar 24, the value is 0.04. This value is within the healthy range. It has decreased from 2.99 (Mar 23) to 0.04, marking a decrease of 2.95.
- For PBT / Share (Rs.), as of Mar 24, the value is 0.04. This value is within the healthy range. It has decreased from 2.12 (Mar 23) to 0.04, marking a decrease of 2.08.
- For Net Profit / Share (Rs.), as of Mar 24, the value is 0.04. This value is below the healthy minimum of 2. It has decreased from 2.12 (Mar 23) to 0.04, marking a decrease of 2.08.
- For PBDIT Margin (%), as of Mar 24, the value is 9.87. This value is below the healthy minimum of 10. It has decreased from 33.83 (Mar 23) to 9.87, marking a decrease of 23.96.
- For PBIT Margin (%), as of Mar 24, the value is 9.20. This value is below the healthy minimum of 10. It has decreased from 33.54 (Mar 23) to 9.20, marking a decrease of 24.34.
- For PBT Margin (%), as of Mar 24, the value is 9.20. This value is below the healthy minimum of 10. It has decreased from 23.83 (Mar 23) to 9.20, marking a decrease of 14.63.
- For Net Profit Margin (%), as of Mar 24, the value is 9.20. This value is within the healthy range. It has decreased from 23.81 (Mar 23) to 9.20, marking a decrease of 14.61.
- For Return on Networth / Equity (%), as of Mar 24, the value is 0.42. This value is below the healthy minimum of 15. It has decreased from 18.38 (Mar 23) to 0.42, marking a decrease of 17.96.
- For Return on Capital Employeed (%), as of Mar 24, the value is 0.42. This value is below the healthy minimum of 10. It has decreased from 25.89 (Mar 23) to 0.42, marking a decrease of 25.47.
- For Return On Assets (%), as of Mar 24, the value is 0.35. This value is below the healthy minimum of 5. It has decreased from 14.66 (Mar 23) to 0.35, marking a decrease of 14.31.
- For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 24, the value is 0.00. This value is within the healthy range. It has decreased from 0.17 (Mar 23) to 0.00, marking a decrease of 0.17.
- For Asset Turnover Ratio (%), as of Mar 24, the value is 0.03. It has decreased from 0.66 (Mar 23) to 0.03, marking a decrease of 0.63.
- For Current Ratio (X), as of Mar 24, the value is 3.68. This value exceeds the healthy maximum of 3. It has increased from 2.88 (Mar 23) to 3.68, marking an increase of 0.80.
- For Quick Ratio (X), as of Mar 24, the value is 3.68. This value exceeds the healthy maximum of 2. It has increased from 2.88 (Mar 23) to 3.68, marking an increase of 0.80.
- For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 4. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 3. There is no change compared to the previous period (Mar 23) which recorded 0.00.
- For Enterprise Value (Cr.), as of Mar 24, the value is 10.60. It has increased from 7.21 (Mar 23) to 10.60, marking an increase of 3.39.
- For EV / Net Operating Revenue (X), as of Mar 24, the value is 64.18. This value exceeds the healthy maximum of 3. It has increased from 2.65 (Mar 23) to 64.18, marking an increase of 61.53.
- For EV / EBITDA (X), as of Mar 24, the value is 650.07. This value exceeds the healthy maximum of 15. It has increased from 7.83 (Mar 23) to 650.07, marking an increase of 642.24.
- For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 64.22. This value exceeds the healthy maximum of 3. It has increased from 2.44 (Mar 23) to 64.22, marking an increase of 61.78.
- For Price / BV (X), as of Mar 24, the value is 2.99. This value is within the healthy range. It has increased from 1.88 (Mar 23) to 2.99, marking an increase of 1.11.
- For Price / Net Operating Revenue (X), as of Mar 24, the value is 64.28. This value exceeds the healthy maximum of 3. It has increased from 2.44 (Mar 23) to 64.28, marking an increase of 61.84.
- For EarningsYield, as of Mar 24, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.09 (Mar 23) to 0.00, marking a decrease of 0.09.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Genomic Valley Biotech Ltd:
- Net Profit Margin: 9.2%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.42% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.42% (Industry Average ROE: 19.15%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.68
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 38.7 (Industry average Stock P/E: 18.14)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.2%
About the Company - Qualitative Analysis
Genomic Valley Biotech Ltd. is a Public Limited Listed company incorporated on 15/03/1996 and has its registered office in the State of Haryana, India. Company's Corporate Identification Number(CIN) is L01122HR1994PLC033029 and registration number is 033029. Currently Company is involved in the business activities of Growing of cucumbers, gherkins, aubergines, tomatoes, watermelons, cantaloupes , melons and other fruit-bearing vegetables. Company's Total Operating Revenue is Rs. 0.17 Cr. and Equity Capital is Rs. 3.05 Cr. for the Year ended 31/03/2024.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Seeds/Tissue Culture/Bio Technology | 4KM Stone, Berry Charra Road, P.O. Tanda Hari, Jhajjar District Haryana 124507 | genomicvalley@gmail.com http://www.genomicvalley.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Yogesh Agrawal | Managing Director |
| Mrs. Parul Agrawal | Non Executive Director |
| Mr. Ashok Kumar | Non Executive Director |
| Mr. Satendra Kumar Goyal | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd's intrinsic value (as of 01 June 2025) is ₹38.82 — 14.87% lower the current market price of 45.60, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 13.9 Cr. market cap, FY2025-2026 high/low of ₹108/33.4, reserves of 0.76 Cr, and liabilities of 4.16 Cr.
What is the Market Cap of Genomic Valley Biotech Ltd?
The Market Cap of Genomic Valley Biotech Ltd is 13.9 Cr..
What is the current Stock Price of Genomic Valley Biotech Ltd as on 01 June 2025?
The current stock price of Genomic Valley Biotech Ltd as on 01 June 2025 is 45.6.
What is the High / Low of Genomic Valley Biotech Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Genomic Valley Biotech Ltd stocks is ₹108/33.4.
What is the Stock P/E of Genomic Valley Biotech Ltd?
The Stock P/E of Genomic Valley Biotech Ltd is 38.7.
What is the Book Value of Genomic Valley Biotech Ltd?
The Book Value of Genomic Valley Biotech Ltd is 12.7.
What is the Dividend Yield of Genomic Valley Biotech Ltd?
The Dividend Yield of Genomic Valley Biotech Ltd is 0.00 %.
What is the ROCE of Genomic Valley Biotech Ltd?
The ROCE of Genomic Valley Biotech Ltd is 11.8 %.
What is the ROE of Genomic Valley Biotech Ltd?
The ROE of Genomic Valley Biotech Ltd is 9.68 %.
What is the Face Value of Genomic Valley Biotech Ltd?
The Face Value of Genomic Valley Biotech Ltd is 10.0.